[go: up one dir, main page]

MX2022004786A - Variante de aav2 con aflibercept para usarse en el tratamiento de una condicion o enfermedad ocular. - Google Patents

Variante de aav2 con aflibercept para usarse en el tratamiento de una condicion o enfermedad ocular.

Info

Publication number
MX2022004786A
MX2022004786A MX2022004786A MX2022004786A MX2022004786A MX 2022004786 A MX2022004786 A MX 2022004786A MX 2022004786 A MX2022004786 A MX 2022004786A MX 2022004786 A MX2022004786 A MX 2022004786A MX 2022004786 A MX2022004786 A MX 2022004786A
Authority
MX
Mexico
Prior art keywords
treatment
aflibercept
aav2
variant
disease
Prior art date
Application number
MX2022004786A
Other languages
English (en)
Inventor
Mark Blumenkranz
Mehdi Gasmi
Original Assignee
Adverum Biotechnologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adverum Biotechnologies Inc filed Critical Adverum Biotechnologies Inc
Publication of MX2022004786A publication Critical patent/MX2022004786A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dispersion Chemistry (AREA)
  • Hematology (AREA)

Abstract

La presente divulgación proporciona composiciones farmacéuticas y métodos de las mismas para el tratamiento de degeneración macular relacionada con la edad (DMRE) en un sujeto al administrar de manera intravítrea una composición farmacéutica adaptada para terapia génica, que comprende un vector que tiene una secuencia de ácido nucleico que codifica aflibercept.
MX2022004786A 2016-06-16 2018-12-13 Variante de aav2 con aflibercept para usarse en el tratamiento de una condicion o enfermedad ocular. MX2022004786A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662351234P 2016-06-16 2016-06-16

Publications (1)

Publication Number Publication Date
MX2022004786A true MX2022004786A (es) 2022-05-16

Family

ID=60663653

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018015512A MX391779B (es) 2016-06-16 2017-06-16 Variante de aav2 con aflibercept para usarse en el tratamiento de una condición o enfermedad ocular.
MX2022004786A MX2022004786A (es) 2016-06-16 2018-12-13 Variante de aav2 con aflibercept para usarse en el tratamiento de una condicion o enfermedad ocular.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2018015512A MX391779B (es) 2016-06-16 2017-06-16 Variante de aav2 con aflibercept para usarse en el tratamiento de una condición o enfermedad ocular.

Country Status (25)

Country Link
US (2) US20190151409A1 (es)
EP (3) EP3471780B1 (es)
JP (5) JP6814822B2 (es)
KR (2) KR20210021113A (es)
CN (2) CN117531025A (es)
AU (3) AU2017286673B2 (es)
BR (1) BR112018076124A2 (es)
CA (1) CA3027737A1 (es)
CY (1) CY1123697T1 (es)
DK (2) DK3795181T3 (es)
ES (2) ES3049818T3 (es)
FI (1) FI3795181T3 (es)
HR (2) HRP20201842T1 (es)
HU (1) HUE051953T2 (es)
IL (3) IL279919B2 (es)
LT (2) LT3795181T (es)
MX (2) MX391779B (es)
PL (1) PL3795181T3 (es)
PT (2) PT3471780T (es)
RS (2) RS67328B1 (es)
SG (1) SG11201811232XA (es)
SI (2) SI3471780T1 (es)
SM (2) SMT202500400T1 (es)
WO (1) WO2017218974A2 (es)
ZA (1) ZA201808538B (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106414474B (zh) 2014-03-17 2021-01-15 阿德夫拉姆生物技术股份有限公司 用于视锥细胞中增强的基因表达的组合物和方法
BR112017018846A2 (pt) 2015-03-02 2018-07-31 Adverum Biotechnologies, Inc. composições e métodos para entrega intravítrea de polinucleotídeos a cones retinianos.
LT3795181T (lt) * 2016-06-16 2025-12-29 Adverum Biotechnologies, Inc. Amd gydymas naudojant aav2 variantą su afliberceptu
AU2017345470B2 (en) 2016-10-19 2023-08-03 Adverum Biotechnologies, Inc. Modified AAV capsids and uses thereof
EA201992001A1 (ru) 2017-03-17 2020-01-24 Адверум Байотекнолоджис, Инк. Композиции и способы повышения экспрессии генов
CN107537026A (zh) * 2017-08-31 2018-01-05 中山大学中山眼科中心 Vegf‑b的应用
CN107661492A (zh) * 2017-08-31 2018-02-06 中山大学中山眼科中心 Vegf‑b的新用途
EP3697449A1 (en) * 2017-10-18 2020-08-26 REGENXBIO Inc. Treatment of ocular diseases and metastatic colon cancer with human post-translationally modified vegf-trap
CN111770999A (zh) 2017-11-27 2020-10-13 4D分子治疗有限公司 腺相关病毒变体衣壳和用于抑制血管生成的应用
MX2020006435A (es) 2017-12-19 2021-02-09 Akouos Inc Administracion de anticuerpos terapeuticos mediada por vector de virus adenoasociado (aav) en el oido interno.
EP3773677B1 (en) * 2018-04-12 2025-04-02 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Anti-aging compositions and methods of use
MX421310B (es) 2018-05-10 2025-03-14 Regeneron Pharma Formulaciones que contienen proteína de fusión del receptor de vegf a alta concentración
WO2020180951A1 (en) * 2019-03-04 2020-09-10 Adverum Biotechnologies, Inc. Sequential intravitreal administration of aav gene therapy to contralateral eyes
CN114144197A (zh) * 2019-04-24 2022-03-04 再生生物股份有限公司 完全人类翻译后修饰的抗体治疗剂
AU2020345915A1 (en) * 2019-09-11 2022-03-24 Adverum Biotechnologies, Inc. Methods of treating ocular neovascular diseases using AAV2 variants encoding aflibercept
CA3147843A1 (en) * 2019-09-11 2021-03-18 Mehdi Gasmi Methods of treating ocular neovascular diseases using aav2 variants encoding aflibercept
US11400039B2 (en) 2020-01-16 2022-08-02 James W. Hill Changing eye color by gene transduction
FR3111913A1 (fr) * 2020-06-30 2021-12-31 Eyevensys Construction d’adn pour le traitement de pathologies oculaires
CN116323949A (zh) * 2020-07-21 2023-06-23 方拓生物科技公司 用于治疗眼部疾病的组合物和方法
CN113952473A (zh) * 2020-07-21 2022-01-21 英斯培瑞有限公司 用于治疗眼部疾病的组合物和方法
CN113952474A (zh) * 2020-07-21 2022-01-21 英斯培瑞有限公司 用于治疗眼部疾病的组合物和方法
CN113817775B (zh) * 2020-08-25 2023-02-17 南京吉迈生物技术有限公司 修饰的阿柏西普、组合物、方法及其在基因治疗中的应用
CA3192736A1 (en) * 2020-09-03 2022-03-10 University Of Massachusetts Adeno-associated virus for delivery of kh902 (conbercept) and uses thereof
PE20240115A1 (es) 2020-12-01 2024-01-22 Akouos Inc Construcciones de anticuerpos anti-vegf y metodos relacionados para el tratamiento de los sintomas asociados al schwannoma vestibular
JP2021049374A (ja) * 2020-12-09 2021-04-01 株式会社三洋物産 遊技機
CA3215855A1 (en) * 2021-04-27 2022-11-03 Julie Clark Methods of treating ocular diseases using aav2 variants encoding aflibercept
CN118660913A (zh) 2022-02-21 2024-09-17 上海瑞宏迪医药有限公司 Vegf结合分子及其医药用途
WO2025072688A2 (en) * 2023-09-27 2025-04-03 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Adeno-associated virus vectors for nucleic acid delivery to retinal cells, for nucleic acid delivery across retinal regions, or for nucleic acid delivery to retinal ganglion cells and/or retinal pigment epithelium cells
WO2025073297A1 (zh) * 2023-10-06 2025-04-10 甘李药业股份有限公司 表达抗vegf融合蛋白的aav病毒载体及其用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3693025T1 (sl) * 2011-04-22 2022-04-29 The Regents Of The University Of California Virioni adeno-povezanega virusa z varianto kapsida in postopki za njihovo uporabo
ES2753135T3 (es) * 2012-05-07 2020-04-07 Allergan Inc Método de tratamiento de DMAE en pacientes resistentes a terapia anti-VEGF
TWI698240B (zh) * 2012-05-15 2020-07-11 澳大利亞商艾佛蘭屈澳洲私營有限公司 使用腺相關病毒(aav)sflt-1治療老年性黃斑部退化(amd)
US20150111275A1 (en) * 2012-06-11 2015-04-23 Daniel V. Palanker Optical regulation of gene expression in the retina
KR20160030396A (ko) * 2013-07-12 2016-03-17 옵쏘테크 코포레이션 안과적 질환을 치료하거나 예방하기 위한 방법
CN105636986B (zh) 2013-10-18 2020-05-12 瑞泽恩制药公司 包含vegf拮抗剂和抗-ctla-4抗体的组合的方法和组合物
BR112017018846A2 (pt) * 2015-03-02 2018-07-31 Adverum Biotechnologies, Inc. composições e métodos para entrega intravítrea de polinucleotídeos a cones retinianos.
LT3795181T (lt) * 2016-06-16 2025-12-29 Adverum Biotechnologies, Inc. Amd gydymas naudojant aav2 variantą su afliberceptu

Also Published As

Publication number Publication date
EP4671369A2 (en) 2025-12-31
RS67328B1 (sr) 2025-11-28
AU2021225178A1 (en) 2021-09-30
KR102218265B1 (ko) 2021-02-25
EP3471780A4 (en) 2019-04-24
CN117531025A (zh) 2024-02-09
BR112018076124A2 (pt) 2019-03-26
IL263686B (en) 2021-02-28
PT3795181T (pt) 2025-11-05
JP2020203941A (ja) 2020-12-24
SG11201811232XA (en) 2019-01-30
PT3471780T (pt) 2020-12-17
SMT202100010T1 (it) 2021-03-15
JP6814822B2 (ja) 2021-01-20
HRP20201842T1 (hr) 2021-04-16
US20190151409A1 (en) 2019-05-23
KR20190037228A (ko) 2019-04-05
RS61311B1 (sr) 2021-02-26
IL314568B1 (en) 2025-05-01
CN109641065A (zh) 2019-04-16
SI3471780T1 (sl) 2021-03-31
EP3471780A2 (en) 2019-04-24
AU2017286673A1 (en) 2019-01-31
LT3795181T (lt) 2025-12-29
WO2017218974A3 (en) 2018-01-25
CY1123697T1 (el) 2022-03-24
MX391779B (es) 2025-03-21
ES2840059T3 (es) 2021-07-06
EP3795181A1 (en) 2021-03-24
HUE051953T2 (hu) 2021-04-28
PL3795181T3 (pl) 2025-12-22
JP2025186377A (ja) 2025-12-23
JP2022137244A (ja) 2022-09-21
LT3471780T (lt) 2021-01-25
AU2021225178B2 (en) 2025-01-30
US20220265740A1 (en) 2022-08-25
WO2017218974A2 (en) 2017-12-21
MX2018015512A (es) 2019-04-24
IL314568B2 (en) 2025-09-01
SI3795181T1 (sl) 2025-11-28
EP3795181B1 (en) 2025-08-06
ES3049818T3 (en) 2025-12-18
IL263686A (en) 2019-01-31
IL279919B2 (en) 2025-01-01
IL279919A (en) 2021-03-01
CA3027737A1 (en) 2017-12-21
FI3795181T3 (fi) 2025-10-14
ZA201808538B (en) 2021-04-28
HRP20251248T1 (hr) 2026-01-16
IL314568A (en) 2024-09-01
EP3471780B1 (en) 2020-10-28
SMT202500400T1 (it) 2025-11-10
JP2024113193A (ja) 2024-08-21
IL279919B1 (en) 2024-09-01
DK3471780T3 (da) 2020-11-23
KR20210021113A (ko) 2021-02-24
AU2017286673B2 (en) 2021-06-24
DK3795181T3 (da) 2025-10-13
AU2025202930A1 (en) 2025-05-15
JP2019521990A (ja) 2019-08-08

Similar Documents

Publication Publication Date Title
MX2022004786A (es) Variante de aav2 con aflibercept para usarse en el tratamiento de una condicion o enfermedad ocular.
CY1125152T1 (el) Συνθεσεις και μεθοδοι για τη μειωση της νεοαγγειωσης του οφθαλμου
EA201890725A1 (ru) Агонисты фарнезоидного х-рецептора и их применение
DOP2018000245A (es) Proteinas de fusion gdf15 y usos de estas
AR099837A1 (es) Terapia génica para la retinitis pigmentaria
EA201892431A1 (ru) Олигонуклеотиды для лечения заболевания глаз
MX392028B (es) Vacunas para el tratamiento y prevención del cáncer.
EP4477662A3 (en) Nucleic acid molecules and uses thereof
DOP2017000191A (es) Nuevas proteínas específicas para pioverdina y pioquelina
BR112017009807A2 (pt) métodos e formulações para tratamento de doenças oculares vasculares
EA201791874A1 (ru) Фторированные ингибиторы лизилоксидазоподобного фермента-2 и их применение
WO2015106128A3 (en) Rnai agents modified at the 4'-c-position
EA201790787A1 (ru) Снижение вязкости фармацевтических составов
BR112019011462A2 (pt) peptídeo coagonista de gip/glp-1, e, peptídeo para uso no tratamento e/ou profilaxia da doença de alzheimer clínica.
BR112017005235A2 (pt) vetores virais adeno-associados para o tratamento de glaucoma de miocilina (myoc)
EA201692402A1 (ru) Лекарственные формы для местного применения и их использование
PE20190397A1 (es) Virus de enteritis de pato y usos del mismo
CL2020002561A1 (es) Composiciones y métodos para el tratamiento de la distrofia macular
CL2017000382A1 (es) Compuestos bicíclicos sustituidos
BR112018008769A2 (pt) formulações farmacêuticas, formulações líquidas aquosa reconstituída e liofilizada, seringa, método de fabricação de uma formulação farmacêutica, método para tratamento de uma doença e uso de uma formulação reconstruída
MX2021012783A (es) Anticuerpos anti-pd-l1 modificados y metodos y usos para el tratamiento de una enfermedad neurodegenerativa.
WO2016103042A8 (en) Compositions and methods for inhibiting expression of adamts-5 and adam17
CL2015003242A1 (es) Virus aav/upr-plus, proteína de fusión upr-plus, método de tratamiento genético y su uso en el tratamiento enfermedades neurodegenerativas, tales como las enfermedades de parkinson y huntington, entre otras.
BR112017007102A2 (pt) uso de um medicamento no tratamento de patologias da córnea, composição oftálmica para uso de um medicamento no tratamento de doenças da córnea e método para preparar a composição oftálmica
WO2020036658A3 (en) Drugs promoting retinal rod photoreceptor survival